​

Genmab (GMAB) Stock Forecast, Price Target & Predictions

OverviewOwnershipChartTranscripts

GMAB Stock Forecast

Genmab (GMAB) stock forecast, based on 17 Wall Street analysts, predicts a 12-month average price target of $41.50, with a high of $49.00 and a low of $34.00. This represents a 42.96% increase from the last price of $29.03.

$20 $26 $32 $38 $44 $50 High: $49 Avg: $41.5 Low: $34 Last Closed Price: $29.03

GMAB Stock Rating

Genmab stock's rating consensus is Buy, based on 17 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 12 Buy (70.59%), 4 Hold (23.53%), 1 Sell (5.88%), and 0 Strong Sell (0.00%).

Buy
Total 17 0 1 4 12 Strong Sell Sell Hold Buy Strong Buy

GMAB Price Target Upside V Benchmarks

TypeNameUpside
StockGenmab42.96%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts345
Avg Price Target$41.00$41.50$42.20
Last Closing Price$29.03$29.03$29.03
Upside/Downside41.23%42.96%45.37%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25152--8
Sep, 25144--9
Aug, 25143--8
Jul, 25143--8
Jun, 25144--9
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 06, 2025Asthika GoonewardeneTruist Financial$49.00$33.5646.01%68.79%
Oct 02, 2025H.C. Wainwright$40.00$31.7725.90%37.79%
Sep 29, 2025Jonathan ChangLeerink Partners$34.00$29.1616.60%17.12%
Sep 23, 2025Michael SchmidtGuggenheim$43.00$28.6050.35%48.12%
Mar 11, 2025Asthika GoonewardeneTruist Financial$45.00$20.26122.11%55.01%
Sep 04, 2024Vikram PurohitMorgan Stanley$31.00$27.4113.10%6.79%
Aug 09, 2024Etzer DaroutBMO Capital$46.00$27.0769.93%58.46%
Jun 27, 2024Kaveri PohlmanBTIG$47.00$25.6783.09%61.90%
Jun 27, 2024Raghuram SelvarajuH.C. Wainwright$50.00$25.7194.48%72.24%
Jun 04, 2024Asthika GoonewardeneTruist Financial$53.00$28.8383.84%82.57%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 27, 2025Johnson RiceBuyBuyhold
Oct 06, 2025Deutsche BankBuyBuyhold
Oct 02, 2025H.C. WainwrightBuyBuyhold
Sep 23, 2025GuggenheimBuyupgrade
Aug 28, 2025Deutsche BankBuyBuyhold
Apr 28, 2025HSBCBuyBuyhold
Mar 10, 2025William BlairMarket PerformOutperformupgrade
Oct 16, 2024H.C. WainwrightBuyBuyhold
Oct 11, 2024Cowen & Co.HoldHoldhold
Sep 20, 2024Johnson RiceBuyBuyhold

Financial Forecast

EPS Forecast

$0 $14 $28 $42 $56 $70 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$7.30$4.60$8.45$66.64-----
Avg Forecast$7.14$4.37$9.88$7.48$8.66$9.62$12.41$17.92$22.36
High Forecast$7.53$4.60$10.45$8.36$9.91$14.02$14.13$20.13$23.89
Low Forecast$6.65$4.06$8.83$6.85$7.76$7.48$8.31$15.91$19.63
Surprise %2.24%5.26%-14.47%790.91%-----

Revenue Forecast

$5B $13B $21B $29B $37B $45B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$10.11B$8.48B$14.60B$16.47B-----
Avg Forecast$9.75B$8.39B$14.05B$16.16B$21.64B$25.39B$29.23B$33.61B$39.61B
High Forecast$10.16B$8.74B$14.68B$16.44B$22.57B$26.31B$29.40B$33.81B$41.70B
Low Forecast$9.23B$7.94B$12.91B$15.89B$20.78B$24.04B$29.06B$33.41B$35.89B
Surprise %3.65%1.10%3.89%1.92%-----

Net Income Forecast

$0 $8B $16B $24B $32B $40B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$4.76B$2.96B$5.45B$4.35B-----
Avg Forecast$29.77B$15.19B$14.90B$4.35B$582.45M$708.62M$739.70M$1.19B$1.47B
High Forecast$35.72B$18.22B$17.88B$5.22B$653.26M$924.29M$931.50M$1.33B$1.57B
Low Forecast$23.81B$12.15B$11.92B$3.48B$511.65M$492.95M$547.90M$1.05B$1.29B
Surprise %-84.02%-80.53%-63.41%------

GMAB Forecast FAQ

Is Genmab stock a buy?

Genmab stock has a consensus rating of Buy, based on 17 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 12 Buy, 4 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Genmab is a favorable investment for most analysts.

What is Genmab's price target?

Genmab's price target, set by 17 Wall Street analysts, averages $41.5 over the next 12 months. The price target range spans from $34 at the low end to $49 at the high end, suggesting a potential 42.96% change from the previous closing price of $29.03.

How does Genmab stock forecast compare to its benchmarks?

Genmab's stock forecast shows a 42.96% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Genmab over the past three months?

  • October 2025: 12.50% Strong Buy, 62.50% Buy, 25.00% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 11.11% Strong Buy, 44.44% Buy, 44.44% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 12.50% Strong Buy, 50.00% Buy, 37.50% Hold, 0% Sell, 0% Strong Sell.

What is Genmab’s EPS forecast?

Genmab's average annual EPS forecast for its fiscal year ending in December 2024 is $8.66, marking a -87.00% decrease from the reported $66.64 in 2023. Estimates for the following years are $9.62 in 2025, $12.41 in 2026, $17.92 in 2027, and $22.36 in 2028.

What is Genmab’s revenue forecast?

Genmab's average annual revenue forecast for its fiscal year ending in December 2024 is $21.64B, reflecting a 31.37% increase from the reported $16.47B in 2023. The forecast for 2025 is $25.39B, followed by $29.23B for 2026, $33.61B for 2027, and $39.61B for 2028.

What is Genmab’s net income forecast?

Genmab's net income forecast for the fiscal year ending in December 2024 stands at $582.45M, representing a -86.62% decrease from the reported $4.35B in 2023. Projections indicate $708.62M in 2025, $739.7M in 2026, $1.19B in 2027, and $1.47B in 2028.